Compare KBSX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | LUNG |
|---|---|---|
| Founded | 1976 | 1995 |
| Country | Taiwan | United States |
| Employees | 382 | N/A |
| Industry | Recreational Games/Products/Toys | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | KBSX | LUNG |
|---|---|---|
| Price | $0.94 | $2.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 8.6K | ★ 671.3K |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | $18.65 | $2.48 |
| Revenue Next Year | $16.31 | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.81 | $1.13 |
| 52 Week High | $1.77 | $2.89 |
| Indicator | KBSX | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 71.07 |
| Support Level | $0.82 | $1.27 |
| Resistance Level | $1.03 | $2.14 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 34.92 | 84.62 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.